July 5, 2007

With its acquisition of BioVeris complete, Roche Diagnostics is the patent owner for electrochemiluminescence (ECL) technology and can expand its immunochemistry business from the human diagnostics field into new market segments such as life sciences research, life science development, patient self-testing, veterinary testing, drug discovery, drug development, and clinical trials.

Roche signed the merger agreement with BioVeris for approximately $600 million on April 4, and finished the deal on June 26.

Roche’s place in immunochemistry is driven by its Elecsys immunochemistry product line, the fastest growing portfolio of the company’s lab diagnostics business.

For more information, visit the company’s Web site.